Clinical Trial

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2026 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2023-02-20; most recent amendment 2026-01-15.
Status change: Recruiting → Active, Not Recruiting 2026-01-15
Status change: Not Yet Recruiting → Recruiting 2023-06-29
Trial Details
NCT Number NCT05737628
Lead Sponsor Byondis B.V.
Conditions Lymphoma
Enrollment 17 participants
Start Date 2024-03-04
Primary Completion 2026-02 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-16